Javascript must be enabled to continue!
Epidemic meningococcal meningitis outbreak due to serogroup-c in Yobe state northeastern Nigeria: risk factors and effect of reactive ring vaccination with pentavalent conjugate meningococcal vaccine
View through CrossRef
Abstract
Background
There had been a lull in the outbreak of epidemic meningococcal meningitis in Yobe State NE Nigeria for over a decade following the introduction of conjugate monovalent meningococcal vaccine against serogroup-A meningitis. However, an outbreak of serogroup C meningococcal meningitis was recorded for the first time in the state in 2024.
Objective
to describe the epidemiology of epidemic meningococcal meningitis outbreak due to serogroup C in Yobe State northeastern Nigeria and assess the effectiveness of reactive focused ring vaccination with conjugate pentavalent meningococcal vaccine (Men5) used for the first time in the state and Nigeria in the control of the outbreak. Methodology: cross sectional descriptive epidemiologic study.
Results
2,948 cases of epidemic meningococcal meningitis and 72 mortalities (CFR 2.4%) were recorded between March and June 2024 in 12 (70.4%) out of 17 local government areas of the state. The highest incidence and mortality was recorded in the age group 1-20 years [2,547 (86.4%)], 54 (CFR 2.1%)] respectively, and lowest in the age group > 40 years [43 (1.5%), 0 (CFR 0.0%)]. Reactive ring vaccination with Men5 was administered to 581, 025 persons aged 1-30 years. There was a significant declined in both the incidence and mortality due to meningococcal meningitis following focused reactive ring vaccination campaign. Few [223, (0.0038%)] mild adverse events following immunization (e.g. mild to moderate pain or swelling or itching at vaccination site, mild headache, fever etc.) were observed among the vaccinees.
Conclusion
The epidemic of meningococcal meningitis due to sero-group C had similar clinical and epidemiologic pattern with previous outbreaks due to serogroup A. The used of mass reactive ring vaccination with Men5 focused on affected communities was both effective and safe in controlling the outbreak as well as preventing mortality due to meningitis in Yobe State northeastern Nigeria.
Title: Epidemic meningococcal meningitis outbreak due to serogroup-c in Yobe state northeastern Nigeria: risk factors and effect of reactive ring vaccination with pentavalent conjugate meningococcal vaccine
Description:
Abstract
Background
There had been a lull in the outbreak of epidemic meningococcal meningitis in Yobe State NE Nigeria for over a decade following the introduction of conjugate monovalent meningococcal vaccine against serogroup-A meningitis.
However, an outbreak of serogroup C meningococcal meningitis was recorded for the first time in the state in 2024.
Objective
to describe the epidemiology of epidemic meningococcal meningitis outbreak due to serogroup C in Yobe State northeastern Nigeria and assess the effectiveness of reactive focused ring vaccination with conjugate pentavalent meningococcal vaccine (Men5) used for the first time in the state and Nigeria in the control of the outbreak.
Methodology: cross sectional descriptive epidemiologic study.
Results
2,948 cases of epidemic meningococcal meningitis and 72 mortalities (CFR 2.
4%) were recorded between March and June 2024 in 12 (70.
4%) out of 17 local government areas of the state.
The highest incidence and mortality was recorded in the age group 1-20 years [2,547 (86.
4%)], 54 (CFR 2.
1%)] respectively, and lowest in the age group > 40 years [43 (1.
5%), 0 (CFR 0.
0%)].
Reactive ring vaccination with Men5 was administered to 581, 025 persons aged 1-30 years.
There was a significant declined in both the incidence and mortality due to meningococcal meningitis following focused reactive ring vaccination campaign.
Few [223, (0.
0038%)] mild adverse events following immunization (e.
g.
mild to moderate pain or swelling or itching at vaccination site, mild headache, fever etc.
) were observed among the vaccinees.
Conclusion
The epidemic of meningococcal meningitis due to sero-group C had similar clinical and epidemiologic pattern with previous outbreaks due to serogroup A.
The used of mass reactive ring vaccination with Men5 focused on affected communities was both effective and safe in controlling the outbreak as well as preventing mortality due to meningitis in Yobe State northeastern Nigeria.
Related Results
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
Regional disparities of full pentavalent vaccine uptake and the determinants in Ethiopia: Mapping and spatial analysis using the EDHS data
Regional disparities of full pentavalent vaccine uptake and the determinants in Ethiopia: Mapping and spatial analysis using the EDHS data
Background
The full pentavalent (DPT-HepB-Hib) vaccination is the main strategy to prevent five communicable diseases in early childhood, especially in countrie...
Outbreaks of serogroup X meningococcal meningitis in Niger 1995–2000
Outbreaks of serogroup X meningococcal meningitis in Niger 1995–2000
SummaryIn the African meningitis belt, the recurrent meningococcal meningitis epidemics are generally caused by serogroup A. In the past 20 years, other serogroups have been detect...
Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011–2017
Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011–2017
Abstract
Background
In 2010–2017, meningococcal serogroup A conjugate vaccine (MACV) was introduced in 21 African meningitis bel...
Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135
Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135
SummarySince the Neisseria meningitidis serogroup W135 epidemic in Burkina Faso in 2002, the neighbouring countries dread undergoing outbreaks. Niger has strongly enhanced the micr...
Vaccines against Meningococcal Diseases
Vaccines against Meningococcal Diseases
Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now availabl...
2724. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naïve Children (2–9 Years)
2724. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naïve Children (2–9 Years)
Abstract
Background
MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine that contains tetanus toxoid a...
Immunogenicity and Complications of the Pentavalent Vaccine in Iranian Children
Immunogenicity and Complications of the Pentavalent Vaccine in Iranian Children
Objective: Vaccination is one of the most convenient and safe preventive care measures available for children. The Pentavalent vaccine which protects against five major infections ...

